Pharmexa reports progress in US breast cancer trial
Preliminary results with HER-2 AutoVac(TM) Protein vaccine are expected before the end of the year
In March 2003 Pharmexa submitted an application to start a clinical phase I trial with the company's HER-2 AutoVac(TM) Protein vaccine to the US health authorities. The application was among other things based on very promising preclinical results, where injections with HER-2 AutoVac(TM) Protein induced antibody levels comparable to therapeutic levels of the monoclonal antibody Herceptin. Herceptin is being marketed with great success for the treatment of metastatic HER-2 positive breast cancer by the international pharmaceutical companies Roche and Genentech.
The clinical trial, which takes place at two US breast cancer centres in Cleveland and Pittsburgh, includes 10 patients with breast cancer. The primary objective of the trial is to evaluate the safety of the HER-2 AutoVac(TM) Protein vaccine. In addition, the ability of the vaccine to activate a specific immune response against cancer cells expressing the HER-2 protein will be evaluated.
Recruitment of patients to the trial has now been completed according to schedule and all 10 patients have started treatment. Based on this, Pharmexa expects to be able to announce preliminary data from the trial before the end of the year.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.